Pharmacokinetics of recombinant hirudin in healthy horses.

This research study investigates the physical effects of a substance called recombinant hirudin on healthy horses, including how the body absorbs, distributes, metabolizes, and excretes it. The findings suggest that recombinant hirudin can be safely used in horses, with further studies required for its use in treating diseased horses.

Research Objective and Methodology

• The primary objective of this study was to understand how recombinant hirudin behaves in the bodies of healthy horses, specifically its pharmacokinetics and coagulatory changes.
• Eight horses were used for the study; two received a single intravenous dose of recombinant hirudin, while six received the same dose subcutaneously every 12 hours over a period of three days.
• The researchers monitored coagulation times and plasma concentration of recombinant hirudin after both intravenous and subcutaneous administration, over 720 minutes for the former and three days for the latter.

Findings and Interpretation

• No systemic or local side effects were observed in any of the horses treated with recombinant hirudin.
• Post intravenous injection, the two horses showed an elimination half-life of recombinant hirudin, which varied between 58 and 80 minutes. This means that it took this long for half of the substance to be removed from the body.
• After subcutaneous administration, the maximal plasma concentration of the substance was found an average of 128 minutes following administration, while the average terminal half-life was notably longer, at 561 minutes.
• The maximum response in terms of activated partial thromboplastin time, a measure of blood clotting, occurred roughly 1.5 hours after administration. A 1.9 fold lengthening as compared to pretreatment measures was noted.

Conclusion and Future Research

• The study concluded that the physical responses to and behaviors of recombinant hirudin in healthy horses closely mirrored those seen in humans and other animal species, implying its potential as a therapeutic agent in equine medicine.
• While the results were promising, the researchers recommend further studies to determine its effectiveness in horses with diseases, before recombinant hirudin can be officially recommended as a treatment option.